PLAY PODCASTS
Should We Be Concerned About Viral Rebound With Antiviral Agents?
Episode 242

Should We Be Concerned About Viral Rebound With Antiviral Agents?

Listen as expert faculty discuss COVID-19 rebound, related to and independent of COVID-19 antiviral treatment.

Decera Clinical Education Infectious Disease Podcast · Fernando Carnavali MD, Rasika Karnik MS MD, Renslow Sherer MD, Joseph Torrisi PharmD BCIDP

December 30, 20224m 48s

Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

Fernando Carnavali, MD; Rasika Karnik, MS, MD; Renslow Sherer, MD; and Joseph Torrisi, PharmD, BCIDP, discuss COVID-19 rebound, including:

  • Prevalence of COVID-19 rebound
  • COVID-19 rebound and antiviral use
  • Management of COVID-19 rebound 

Presenters:

Fernando Carnavali, MD
Associate Professor of Medicine
Division Chief
General Internal Medicine
Department of Medicine
Site Director 
COVID Center of Excellence Satellite-Ansonia 
Mount Sinai Health 
New York, New York

Rasika Karnik, MS, MD
Assistant Professor
Division of Primary Care
Department of Internal Medicine
University of Chicago
Medical Director
Post-COVID Recovery Clinic
Chicago, Illinois

Renslow Sherer, MD
Director
International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois

Joseph Torrisi, PharmD, BCIDP
Clinical Pharmacy Specialist
Infectious Diseases 
Pharmacy
Grady Health System
Atlanta, Georgia

Link to slides: 
https://bit.ly/3hXMgId

Link to full program: 
https://bit.ly/3G271KL


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Topics

ritonavircovid reboundnirmatrelvir plus ritonavirviral reboundpaxlovidtreatment coursemolnupiravirreboundsars-cov-2 reboundnirmatrelvir + ritonavircovid-19covid-19 reboundcovidantiviral agentsnirmatrelvirlagevrioantiviralsars-cov-2